Akihiro Tomita

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells

Keisuke Watanabe, Seitaro Terakura, Anton C. Martens et al. · The Journal of Immunology · 2014 · 285 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Junji Hiraga, Akihiro Tomita, Takumi Sugimoto et al. · Blood · 2009 · 258 citations · Full text

Medicine, Immunology, Oncology +14

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study

Shigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki et al. · Clinical Infectious Diseases · 2015 · 149 citations · Full text

Medicine, Hematology, Oncology +15